Denali Therapeutics: Two Shots On Goal Fo... - Cure Parkinson's

Cure Parkinson's

26,504 members27,915 posts

Denali Therapeutics: Two Shots On Goal For Parkinson's Disease Treatment

1 Reply

Summary

Denali Therapeutics initiated a phase 3 study, using BIIB122 for the treatment of Parkinson's Disease patients with the pathogenic mutation of LRRK2, in October of 2022.

The company initiated a phase 2b study, using BIIB122 for the treatment of early-stage Parkinson's Disease patients, in May of 2022.

Both studies using BIIB122 for the treatment of patients with Parkinson's Disease are being done in collaboration with Biogen.

It is expected that the global Parkinson's Disease Market will reach a value of $6.70 billion by 2030

seekingalpha.com/article/45...

1 Reply
jeffmayer profile image
jeffmayer

what is classed as early stage

Not what you're looking for?

You may also like...

Stem Cells Trials

I want to make a list here. Please reply with links...

The naturally occurring molecule N-acetylcysteine (NAC) shows benefit in a clinical trial for Parkinson's Disease.

N-acetylcysteine (NAC) is a naturally occurring molecule that replenishes one of the body's...
Farooqji profile image

Bayer’s BlueRock Therapeutics Establishes European Site For Cell Therapy Innovation on Bayer’s campus in Berlin

Bayer has announced that BlueRock Therapeutics has established a new site for cell therapy...

Phase 3, the Lighthouse study, Biogen and Denali, LRRK2 inhibitor BIIB122; New clinical trial registered

New clinical trial registered: Biogen and Denaliti have initiated the 2nd late-stage study of...

"First ever successful experimental stem cell therapy for Parkinson's Disease"

https://youtu.be/Cz_0T7A7xc4?si=X7X0UCasxigtSmPf "Oct 9, 2023 #parkinsonsdisease...
MBAnderson profile image